Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury
- PMID: 17943135
- DOI: 10.1038/nrc2247
Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury
Abstract
Gene-directed enzyme-prodrug therapy (GDEPT) aims to improve the therapeutic ratio (benefit versus toxic side-effects) of cancer chemotherapy. A gene encoding a 'suicide' enzyme is introduced into the tumour to convert a subsequently administered non-toxic prodrug into an active drug selectively in the tumour, but not in normal tissues. Significant effects can now be achieved in vitro and in targeted experimental models, and GDEPT therapies are entering the clinic. Our group has developed a GDEPT system that uses the bacterial enzyme carboxypeptidase G2 to convert nitrogen mustard prodrugs into potent DNA crosslinking agents, and a clinical trial of this system is pending.
Similar articles
-
Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.Cancer Res. 2007 May 15;67(10):4949-55. doi: 10.1158/0008-5472.CAN-07-0297. Cancer Res. 2007. PMID: 17510425
-
Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2.Cancer Res. 2005 Jun 15;65(12):5003-8. doi: 10.1158/0008-5472.CAN-05-0393. Cancer Res. 2005. PMID: 15958540
-
Self-immolative nitrogen mustard prodrugs for suicide gene therapy.J Med Chem. 1998 Dec 17;41(26):5297-309. doi: 10.1021/jm980425k. J Med Chem. 1998. PMID: 9857097
-
Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.Curr Opin Mol Ther. 1999 Aug;1(4):480-6. Curr Opin Mol Ther. 1999. PMID: 11713763 Review.
-
Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.Anticancer Drug Des. 1995 Jul;10(5):361-72. Anticancer Drug Des. 1995. PMID: 7639927 Review.
Cited by
-
The fourth front against cancer. The first clinical trials to test engineered viruses that attack tumour cells have yielded promising results for future cancer therapies.EMBO Rep. 2011 Jul 29;12(8):769-71. doi: 10.1038/embor.2011.138. EMBO Rep. 2011. PMID: 21799527 Free PMC article. No abstract available.
-
Glucarpidase to combat toxic levels of methotrexate in patients.Ther Clin Risk Manag. 2012;8:403-13. doi: 10.2147/TCRM.S30135. Epub 2012 Nov 22. Ther Clin Risk Manag. 2012. PMID: 23209370 Free PMC article.
-
Prodrug enzymes and their applications in image-guided therapy of cancer: tracking prodrug enzymes to minimize collateral damage.Drug Deliv Transl Res. 2012 Feb 1;2(1):22-30. doi: 10.1007/s13346-011-0052-0. Drug Deliv Transl Res. 2012. PMID: 23646292 Free PMC article.
-
Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.Oncolytic Virother. 2013 Dec 5;3:1-9. doi: 10.2147/OV.S36703. eCollection 2014. Oncolytic Virother. 2013. PMID: 27512659 Free PMC article. Review.
-
Small molecules aimed at type III secretion systems to inhibit bacterial virulence.Medchemcomm. 2013 Jan 1;4(1):68-79. doi: 10.1039/C2MD20213A. Medchemcomm. 2013. PMID: 23930198 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical